Climb Bio Stock Up After FDA Fast-Track Nod: BTIG reiterated Buy on Apr 7, 2026 after Climb Bio received FDA Fast Track designation in early April 2026; regulatory acceleration alters timelines and investor… 👈 Read full analysis #ClimbBio #FDANews #BiotechInvesting #StockMarket #Investing
Zenas BioPharma CEO Buys $1.02M Stock: Zenas BioPharma CEO bought $1.02M of shares (Investing.com, Apr 1, 2026); institutional analysis of governance signal and implications for small-cap biotech. 👈 Read full analysis #ZenasBioPharma #StockMarket #BiotechInvesting #CEOInvestment #SmallCapStocks
Puma Biotechnology: Nerlynx Revenue Up 15% Q4 2025: Puma Biotechnology reported Nerlynx revenue rose 15% sequentially in Q4 2025 (slides published Mar 28, 2026); investors should seek corroboration in Q1/Q2… 👈 Read full analysis #PumaBiotechnology #Nerlynx #Q42025 #Pharmaceuticals #BiotechInvesting
Day One Biopharmaceuticals: Surge Ahead!
$DAWN stock remains Strong Buy with 2026 milestones & OJEMDA growth
#DAWNstock #BiotechInvesting #StrongBuy
https://a777.lt/ykZkNV
All set for an exciting day at Biocapital Europe in Amsterdam #Inverna #BioCapital2026 #Biotech #RNA #SpliceModulation #Neurodegeneration #ParkinsonsDisease #HuntingtonsDisease #PrecisionMedicine #BiotechInvesting #Partnering
Women Drive Biotech Innovation: $BMY & $GILD Lead Charge
Women lead precision medicine advancements, driving phase 1 programs & new drug models
#BiotechInvesting #PrecisionMedicine #WomenInSTEM
https://a777.lt/v8vKAr
Deal takeaways - Strong platform validation for Shengyin’s RNAi chemistry and delivery technologies - Meaningful non-dilutive capital with retained upside via milestones and royalties - Genentech assumes late-stage development and commercialization risk, a classic risk-sharing structure - Signals continued Big Pharma appetite for RNAi assets, especially platform-driven programs From an investment perspective, this deal highlights how differentiated RNA platforms can command premium economics even at early clinical stages—and how large pharma is selectively re-entering RNAi with improved delivery solutions.
RNAi deal worth watching from an investment lens
SanegeneBio announced a global licensing agreement with Genentech (罗氏公司 Group) for an RNAi therapeutic, featuring $200M upfront, up to $1.5B in milestones, plus tiered royalties.
#BiotechInvesting #RNAi #LicensingDeals #PharmaBD #Roche #Genentech
Investors should be aware of "p-hacking" strategies used in data analysis: For biotech, I have come across #s 3, 6, 8-11 too often
Hard to know without raw data but be prepared to ask & investigate where possible!
#learnbiotechinvesting #biotechinvesting #BiotechPrometheus
As shares rebound, investors are weighing whether the biotech’s cancer pipeline could define its next chapter.
longevity.technology/news/biontec...
#longevity #biotechinvesting #mRNA #cancerresearch #biotechnews #futuremedicine
In antibody therapeutics, large pharma continues to pay for platforms that explicitly address therapeutic index. The 百时美施贵宝-Janux Therapeutics collaboration around a tumor-activated T cell engager reinforces that conditional activation remains one of the most credible strategies for expanding the use of TCEs in solid tumors. When platform design is anchored in safety control rather than brute-force potency, preclinical assets can still command meaningful economics. A similar logic appears in autoimmune disease. 勃林格殷格翰’s billion-euro-scale bet on a TL1A×IL-23 bispecific reflects confidence that pathway convergence, rather than incremental single-target optimization, may be required to reset efficacy ceilings in chronic inflammatory diseases. Importantly, these deals continue to offload late-stage clinical and commercial execution to scaled operators, allowing early innovators to monetize platform risk earlier. What stands out this week, however, is the contrast provided by gene medicine. 礼来’s >$1.1B collaboration with Seamless Therapeutics around a programmable recombinease platform for hereditary hearing loss highlights that gene therapy capital is re-entering the market—but in a more disciplined form. The emphasis is no longer on editing novelty alone, but on programmability, precision, and clinical tractability. In many ways, this mirrors where antibody investing was a decade ago. Two cross-modality patterns are becoming clearer: - Platform optionality is favored over single-asset heroics - Safety, controllability, and manufacturability increasingly drive valuation - Big pharma prefers structured deals that preserve downside while securing long-term upside The antibody and gene therapy worlds are converging—not in modality, but in investment logic. The next winners will be platforms that convert uncertainty into engineering problems.
This week’s deal flow sends a clean signal: capital is not retreating from innovation—it is becoming more selective about where technical risk is taken and how it is transferred.
#BCIC #BiotechInvesting #AntibodyTherapeutics
#TCellEngagers #BispecificAntibodies #ADC
#GeneTherapy #RareDisease
Why China’s early-stage drugmaking edge is the most compelling “de-risked” opportunity in 2026.
Source: lnkd.in/ezEfyWRm
#BCIC #Bostoncapitalinvestmentclub #BiotechInvesting #VentureCapital #DrugDiscovery #AssetAllocation #CGT #ADC
Images generated with insights from Pitchbook 2026 Report.
Dr. Ann Childress, principal investigator on Cingulate’s CTx-1301 trials, highlights some of the differences in ADHD symptoms between children and adults.
#ADHD #Neuroscience #Biotech #SmallCapBiotech #BiotechInvesting #ClinicalPipeline #DrugDevelopment #NASDAQ
Dr. Ann Childress describes how the new #ADHD medication CTx-1301 works in this brief clip.
$CING
#Cingulate #Biotech #ClinicalTrials #LifeSciences #ADHDResearch #BiotechInvesting #PharmaNews #NASDAQ
#Vivus’ John Amos on AI, the #FDA and what it’s like to work with the agency.
#Biopharma #Pharmaceuticals #Biotechnology #DrugDevelopment #Therapeutics #ObesityTreatment #CardiometabolicHealth #PharmaNews #BiotechInvesting #Biotech
China's biotech stocks soar 60% this year, outpacing even AI. Are you ready to invest in this booming sector? #BiotechInvesting
www.bloomberg.com/news/articles/2025-06-15...
Looking to connect with those on #bluesky that are interested in #scicomm #healthcareinvesting #research #biotechinvesting
Algorithm do your magic!
makes this purchase in such a difficult environment noteworthy.
bit.ly/4jn1uB6
#InsiderBuying #TheInsidersFund #SVRA #RareDiseases #BiotechInvesting
Introducing: The AI Biotech Fund, a wholesale only innovative investment vehicle focused on generating significant capital appreciation by leveraging advanced AI-driven strategies. Open to wholesale investors only. Enquire now: aibiotechfund.com
#asx #nasdaq #nyse #cboe #biotechinvesting
We’re excited to announce a strategic partnership with Avion, a leading full-service CRO, to bring TrialKey's AI-powered insights to clinical trial design and execution. #asx #biotech #biotechnews #biotechinvestment #biotechinvesting #asxnews
Biotech is evolving fast, but could $CYBN hold the key to the next big breakthrough? 🧬💊 Imagine being an early investor in a company revolutionizing mental health treatments.
www.wizeinvesting.com/p/cybin-stoc...
#BiotechInvesting #CYBN #StockAnalysis #FinancialGrowth #InvestingTips
As biotech stocks gear up for 2025, what catalysts do you think will drive their success? Weight-loss drugs, AI, or Trump 2.0? #BiotechInvesting
www.investors.com/news/technology/biotech-...
